The landscape of obesity and type 2 diabetes (T2D) management is rapidly evolving with the growing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other pharmacologic weight-loss agents. Recent data show that 12% of U.S. adults have used a GLP-1 medication at some point. Over the past five years, GLP-1 use among patients with diabet

Introduction Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous subtype of non-Hodgkin lymphoma and remains the most common form globally (1). While standard first-line therapy with R-CHOP has cured over 60% of patients, approximately 40% of patients experience relapse or become refractory to treatment, highlighti

Introduction Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a significant therapeutic challenge, particularly in patients who are ineligible for transplant or have progressed after standard treatments (1). Emerging therapeutic strategies, such as cereblon E3 ligase modulators (CELMoDs), are being explored to address this u

In this expert KOL interview, Dr. Naveen Kumar Mattewada, Senior Nephrologist from Hyderabad, shares 2025 updates on glomerular diseases, covering biopsy advances, biomarkers, and new therapies. Essential insights for nephrologists and physicians managing kidney disease and proteinuria. 🔍 Key Topics: Evolving trends in glomerular disease Advances

Celiac disease is a chronic immune-mediated condition affecting roughly 1% of the population. Triggered by ingestion of gluten proteins (found in wheat, rye, and barley) in genetically susceptible individuals, its current treatment remains a lifelong strict gluten‑free diet (GFD). While GFD effectively reduces symptoms and intestinal damage in most

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now central to managing type 2 diabetes and obesity, with growing potential in cardiovascular, kidney, and neurodegenerative diseases like Parkinson’s. As their use expands, concerns about ocular safety have emerged. These concerns began with the SUSTAIN-6 trial, which linked semaglutide to

A 52-year-old male with a past medical history of hypertension for 2 years, on telmisartan 40 mg once daily developed pruritic, purplish, raised, and painless lesions over the scalp and dorsum of the hands and feet for 4 months. He was initially treated with oral antihistamines and topical clobetasol that provided partial relief over 20 days but la

Introduction Secukinumab, a fully human monoclonal antibody, targets interleukin-17A (IL-17A), a pro-inflammatory cytokine implicated in giant cell arteritis (GCA) (1). This Phase III trial evaluates the efficacy and safety of secukinumab 300 mg administered subcutaneously (SC) over 52 weeks, alongside a 26-week prednisone taper, in approximately 2

Introduction Ankylosing spondylitis (AS) is a chronic inflammatory condition of the axial skeleton, treated initially with NSAIDs (1). For patients with active disease despite conventional therapy, biologics like TNF-α or IL-17A inhibitors are recommended (1). Secukinumab, a first-in-class IL-17A inhibitor, is approved for AS, plaque psoriasis, and